Nourhan Zahran

Dr. Nourhan Zahran

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
NZNourhan Zahran
Nourhan Zahran
Abdelghafar M. Abu-ElsaoudAbdelghafar M. Abu-Elsaoud
Abdelghafar M. Abu-Elsaoud
AMAyman Saber Mohamed
Ayman Saber Mohamed
OMohoud m. marie
ohoud m. marie
Background: Obesity, characterized by an abnormal and excessive accumulation of fat, significantly affects health by increasing the probability of chronic diseases and has become a pressing global health issue. Among natural compounds with therapeutic potential, rutin exhibits diverse biological effects, such as antioxidant, anti-inflammatory, and hypolipidemic properties. Objective: The purpose of this work is to evaluate the preventive effects of rutin loaded on chitosan nanoparticles on metabolic and oxidative alterations in male albino rats fed a high-fat diet (HFD). Method: The rats were allocated to four distinct groups: control, HFD, HFD treated with 50 mg/kg rutin, and HFD treated with 50 mg/kg nano-rutin, respectively, for six weeks. Results: Molecular docking analysis revealed that rutin exhibits an inhibitory interaction with PPAR-γ, suggesting its potential role in suppressing adipogenesis and contributing to its preventive effect against obesity. Nano-rutin markedly improved glycemic control, reducing fasting glucose from 161.75 ± 8.37 mg/dL in the HFD group to 133.50 ± 3.55 mg/dL, compared to 92.17 ± 3.53 mg/dL in controls. Serum leptin levels decreased from 28.95 ± 1.06 ng/mL in the HFD group to 15.58 ± 0.65 ng/mL with nano-rutin, approaching the control value of 10.43 ± 0.80 ng/mL. Oxidative stress was also significantly alleviated, as shown by a reduction in malondialdehyde (MDA) from 8.43 ± 0.20 U/µL in HFD rats to 6.57 ± 0.08 U/µL with nano-rutin, versus 1.29 ± 0.13 U/µL in controls. Conclusions: Rutin loaded on chitosan nanoparticles demonstrated protective effects against high-fat diet-induced obesity, mainly through modulation of leptin signaling and oxidative stress pathways. These findings highlight the promise of nano-rutin as a natural agent for preventing metabolic disorders related to obesity.

1 November 2024 in Journal of Medicinal and Chemical Sciences
Verified
Other
Open access
PDF file
FAFutoon Abedrabbu Al-Rawashde
Futoon Abedrabbu Al-Rawashde
LALaila Al-Omari
Laila Al-Omari
HSHanan Kamel M. Saad
Hanan Kamel M. Saad
MAmoath alqaraleh
moath alqaraleh
NZNourhan Zahran
Nourhan Zahran
Hamid Al-JamalHamid Al-Jamal
Hamid Al-Jamal
Mutations in FLT3 prompt hyperactivation of RAS/RAF/MEK/ERK growth signalling. The FLT3-D835Y mutation confers resistance to FLT3 inhibitors for acute myeloid leukemia (AML) therapy. The KRAS-G12C and BRAF-V600E are frequent mutations in several cancers. While inhibitors against RAS, RAF, MEK, and ERK are available, they are often unsuccessful against BRAF or KRAS mutations with reported toxicity rates. This study evaluates the potential of thymoquinone (TQ), a phytochemical obtained from Nigella sativa seed, to function as an inhibitor of FLT3-D835Y, KRAS-G12C, BRAF-V600E, MEK, and ERK and to modify the expressions of genes related to RAS/RAF/MEK/ERK signaling in MV4-11 AML cells. The cells were incubated with TQ and we utilized RT-qPCR to measure the target genes’ mRNA levels. Molecular docking of TQ and reference inhibitors to FLT3-D835Y, KRAS-G12C, BRAF-V600E, MEK, and ERK proteins was examined with calculations of binding energies. TQ produced significantly downregulated K-RAS, B-RAF, MEK1, and ERK2 expressions. TQ also docked to FLT3-D835Y, KRAS-G12C, BRAF-V600E, MEK1, and ERK2 with high binding affinities and low docking scores. The study identifies TQ as an inhibitor of multiple target mutations that could combat resistance to FLT3-D835Y, KRAS-G12C, and BRAF-V600E inhibitors, aiding in the improvement of AML therapy.